Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 3, 2026, 6:53 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 49–72 of 136 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Cardiomyopathy, Hypertrophic Clear all
Withdrawn No phase listed Observational

Use of Magnetic Field Mapping in the Evaluation of Patients With Hypertrophic Heart Disease (Thick Heart Muscle)

NCT00574821
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
16 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 17, 2009 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Analysis of Heart Muscle Function in Patients With Heart Disease and Normal Volunteers

NCT00001459
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic, Coronary Disease, Healthy, Myocardial Ischemia, Syndrome X
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
150 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1995 – 2001
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational

Long Term Effects of Enalapril and Losartan on Genetic Heart Disease

NCT00001534
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Hypertrophy, Myocardial Ischemia
Interventions
Losartan
Drug
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
112 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1996 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 2 Interventional

Alcohol Septal Ablation in Obstructive Hypertrophic Cardiomyopathy: A Pilot Study

NCT00035386
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
trans-right ventricular alcohol septal ablation (TRVASA)
Procedure
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational

Heart and Skeletal Muscle Problems in Neuroacanthocytosis

NCT00007228
View directory record Official record
Conditions
Choreatic Disorder
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
Not listed
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2003
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 4, 2008 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational

Patients' Long-Term Survival of Obstructive Hypertrophic Cardiomyopathy (HCM)

NCT04603521
View directory record Official record
Conditions
Cardiomyopathy, Obstructive Hypertrophic Cardiomyopathy
Interventions
Not listed
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years and older
Enrollment
325 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 1, 2022 · Synced Oct 3, 2026, 6:53 PM EDT
Active, not recruiting Phase 4 Interventional

A Study to Evaluate Mavacamten Impact on Myocardial Structure in Participants With Symptomatic Obstructive Hypertrophic Cardiomyopathy

NCT06112743
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
63 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
7
States / cities
West Hollywood, California • Atlanta, Georgia • Boston, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 3, 2026, 6:53 PM EDT
Active, not recruiting No phase listed Observational

COLLIGO-HCM: A Multinational Observational Study of the Real-World Effectiveness of Mavacamten Among Patients With Symptomatic Obstructive Hypertrophic Cardiomyopathy (oHCM)

NCT06372457
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
Approved Hypertrophic Cardiomyopathy drug treatments, Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
331 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Sep 30, 2026 · Synced Oct 3, 2026, 6:53 PM EDT
Recruiting No phase listed Observational

Mavacamten Pregnancy Surveillance Program

NCT05939700
View directory record Official record
Conditions
Breastfeeding, Hypertrophic Cardiomyopathy, Pregnancy Related
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
15 Years and older · Female only
Enrollment
20 participants
Timeline
2023 – 2027
U.S. locations
1
States / cities
Wilmington, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 6, 2025 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 1 Interventional

Natural History and Results of Dual Chamber (DDD) Pacemaker Therapy of Children With Obstructive Hypertrophic Cardiomyop...

NCT00001396
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
Paragon Pacemaker
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
5 Years to 20 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1993 – 2008
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 2, 2017 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 1 Interventional Results available

Hypertrophic Regression With N-Acetylcysteine in HCM

NCT01537926
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy
Interventions
N-acetylcysteine, Placebo
Drug
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 2, 2021 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational

Hypertrophic Cardiomyopathy Pilot Study

NCT02806479
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Coronary Artery Disease
Interventions
Observational: Arrhythmogenic Substrate
Other
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years to 99 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Sep 16, 2020 · Synced Oct 3, 2026, 6:53 PM EDT
Active, not recruiting No phase listed Observational

Perfusion Abnormalities in Hypertrophic Cardiomyopathy

NCT06599229
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy (HCM)
Interventions
myocardial contrast echo
Diagnostic Test
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Apr 16, 2026 · Synced Oct 3, 2026, 6:53 PM EDT
Not listed Phase 1 Interventional

Gene Therapy for Male Patients With Danon Disease (DD) Using RP-A501; AAV9.LAMP2B

NCT03882437
View directory record Official record
Conditions
Danon Disease
Interventions
RP-A501
Biological
Lead sponsor
Rocket Pharmaceuticals Inc.
Industry
Eligibility
8 Years and older · Male only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
3
States / cities
La Jolla, California • Aurora, Colorado • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 3, 2026, 6:53 PM EDT
Not listed No phase listed Observational Accepts healthy volunteers

Exercise Study Including Patients With Hypertrophic Cardiomyopathy

NCT01165749
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
stop exercising
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Jul 20, 2010 · Synced Oct 3, 2026, 6:53 PM EDT
Recruiting Phase 1 Interventional

Phase IA and IB Study of AAVrh.10hFXN Gene Therapy for the Cardiomyopathy of Friedreich's Ataxia

NCT05302271
View directory record Official record
Conditions
Friedreich Ataxia, Cardiomyopathies, Cardiac Hypertrophy, Myocardial Fibrosis
Interventions
AAVrh.10hFXN, serotype rh.10 adeno-associated virus (AAV) gene transfer vector expressing the cDNA coding for human FXN, Prednisone
Biological · Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
12 Years to 50 Years
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational

Mavacamten in Obstructive Hypertrophic Cardiomyopathy

NCT07168655
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Mavacamten
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
163 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 11, 2025 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

NCT04164732
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic
Interventions
LCZ696, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2023
U.S. locations
5
States / cities
Stanford, California • Boston, Massachusetts • Ann Arbor, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 3, 2026, 6:53 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults With Symptomatic oHCM

NCT05186818
View directory record Official record
Conditions
Obstructive Hypertrophic Cardiomyopathy (oHCM)
Interventions
Aficamten (5 mg, 10 mg, 15 mg, and 20 mg), Placebo to match aficamten
Drug
Lead sponsor
Cytokinetics
Industry
Eligibility
18 Years to 85 Years
Enrollment
282 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
48
States / cities
Anchorage, Alaska • La Jolla, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2026 · Synced Oct 3, 2026, 6:53 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Human Experimental Models of Pain (HEMP)

NCT07549490
View directory record Official record
Conditions
Acute Pain
Interventions
Placebo, Naproxen, Pregabalin
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
18 Years to 100 Years
Enrollment
25 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 3, 2026, 6:53 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

AI-Enabled Direct-from-ECG Ejection Fraction (EF) Severity Assessment Using COR ECG Wearable Monitor

NCT06699056
View directory record Official record
Conditions
Ventricular Ejection Fraction, LVF, LV Dysfunction, Atrial Enlargement, Conduction Defect, Heart Failure, Valvular Heart Disease, Ischemic Heart Disease, Cardiotoxicity, Myocardial Infarction, Dilated Cardiomyopathy, HFrEF - Heart Failure With Reduced Ejection Fraction, HFpEF - Heart Failure With Preserved Ejection Fraction, Syncope, Remodeling, Cardiac
Interventions
15-minutes of sitting during COR ECG Acquistion
Device
Lead sponsor
Peerbridge Health, Inc
Industry
Eligibility
18 Years and older
Enrollment
2,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
8
States / cities
Orange, California • Pasadena, California • Detroit, Michigan + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 3, 2026, 6:53 PM EDT
Completed No phase listed Observational

Extended ECG Monitoring in HCM Patients

NCT04056715
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Nonsustained Ventricular Tachycardia, Ventricular Tachycardia, Atrial Fibrillation, Arrhythmia
Interventions
Zio XT
Device
Lead sponsor
iRhythm Technologies, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 1, 2023 · Synced Oct 3, 2026, 6:53 PM EDT
Terminated Phase 1 Interventional

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CT-G20 in Subjects With Obstructive Hypertrophic Cardiomyopathy

NCT04418297
View directory record Official record
Conditions
Cardiomyopathy, Hypertrophic Obstructive
Interventions
CT-G20, Placebo
Drug
Lead sponsor
Celltrion
Industry
Eligibility
18 Years to 70 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2022
U.S. locations
3
States / cities
Los Angeles, California • Boston, Massachusetts • New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 3, 2026, 6:53 PM EDT
Terminated Not applicable Interventional Results available

NHLBI SESAME (SEptal Scoring Along Midline Endocardium) Early Feasibility Study

NCT06269640
View directory record Official record
Conditions
Hypertrophic Cardiomyopathy, Left Ventricular Septal Hypertrophy, Mitral Valve Disease, Aortic Valve Stenosis
Interventions
Septal Scoring Along Midline Endocardium
Device
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
21 Years to 99 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 3, 2026, 6:53 PM EDT